Sentences with phrase «after cancer therapy»

Hospice Care — compassionate care administered to an animal patient prior to euthanasia but after cancer therapy stops working.

They survive after cancer therapy and replenish the cancerous mass, leading to relapse.

«And if you have symptoms of heart problems like shortness of breath or swelling in the feet or legs, seek attention quickly, preferably with doctors familiar and comfortable with treating heart failure after cancer therapy.»

Not exact matches

The therapy had an outsized effect in African American men, helping those with metastatic castrate - resistant prostate cancer live a median 37.3 months after treatment.

After all, «biotech» is a pretty broad category that encompasses everything from next - gen cancer therapy makers that are already on the market and racking up sales to firms that are still years away from even filing for their first FDA approval.

Gilead's therapy (which the biotech giant acquired after snapping up developer Kite Pharma for just under $ 12 billion at the end of the summer) is approved for certain types of the blood cancer non-Hodgkin lymphoma.

Adoptive cell therapy for hard - to - treat blood cancers, after all, are widely expected to be the standard of care within a decade, and it should therefore grow to become one of the most lucrative markets in all of biotech.

The FDA approved a Lutetium - 177 based cancer therapy called Lutathera for the treatment of neuroendocrine tumors earlier this year, after Novartis snapped up the developer, Advanced Accelerator, at a premium.

It's great your first friend got over their cancer (or rather went into remission) but it was after chemo and therapy, so was it prayer / god or was it the chemo?

Higgins, S., Haffty, B. Pregnancy and lactation after breast - conserving therapy for early stage breast cancer.

Women who have had breast cancer may not be able to breastfeed after radiation therapy or a mastectomy.

This study analyzed preserved tumor samples from 43 prostate cancer patients who later received radiation therapy after rising PSA levels were detected following a radical prostatectomy.

A new study has identified a group of molecules in prostate - cancer cells that doctors might one day use to distinguish which patients should be treated with radiation therapy if rising PSA levels indicate their cancer has recurred after surgical removal of the prostate.

The type, intensity and duration of immunosuppressive therapy contribute to the risk of developing skin cancer, such as melanoma, after transplantation.

The findings, published online Nov. 13 in Science Translational Medicine, could pave the way for improvements in preventing GVHD and rejection of transplanted bone marrow and new therapies to prevent or treat a relapse of the underlying cancer after a transplant.

The findings inject hard facts into a debate that has long divided the medical community, with many radiation oncologists preferring adjuvant therapy — radiation given soon after prostate removal to kill off any remaining cancer cells — and many urologists preferring salvage therapy — radiation given later, when prostate - specific antigen tests suggest it's needed.

In all, 153 (0.24 %) people developed stomach cancer after triple therapy.

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

Glioblastoma is one of the most difficult cancers to treat — even after surgery and other therapies, it usually kills people within a year of diagnosis.

In science news around the world, NASA's Cassini mission is about to take its final plunge into the atmosphere of Saturn after 13 years providing an unprecedented view of the planet and its moons, a fight over whether to preserve or develop of one Europe's oldest gold mining sites heats up again, the U.S. Food and Drug Administration approves the first cancer gene therapy for people, a U.S. court gives a green light to a $ 1 billion lawsuit brought by the Guatemalan victims and survivors of mid — 20th century syphilis experiments by research institutions including Johns Hopkins University, and more.

That's when a women's health study, stopped early after a data review, published results linking a common hormone therapy to an increased risk of breast cancer, heart disease, stroke and blood clots.

The researchers hope that ultimately human trials will prove the efficacy of the OH14 compound in sensitising tumour cells and cancer stem cells to existing drug - based therapies thus disabling tumours from seeding new growth after treatment.

These cancer stem cells act like the seeds of cancer and are responsible for re-growing a tumor after therapy.

With these in vitro test methods, the KU researchers have shown that anti-CD44s antibody can reduce pancreatic cancer cell growth, metastasis and ability of the tumors to recur after radiation therapy.

Now that we know more about how cancer originates and how tumors re-grow after treatment, we can design new therapies to prevent this.

«In order to block tumor recurrence after radiation therapy, we used an antibody to target and inhibit these cancer stem cells,» said Dr. Xu.

In some cases, a minority of cells called TICs, or cancer stem cells, are culpable of repopulating the tumor after therapy.

In 2001 the trend reversed: Breast cancer rates initially dipped gradually, but dropped sharply in mid-2002, when many women in the U.S. stopped hormone replacement therapy after the Women's Health Initiative, a large clinical trial involving estrogen - progestin therapy, was stopped after it was determined that the risks — most notably the increased likelihood of developing breast cancer — outweighed the benefits.

The U.S. study testing the long - term benefits and risks of hormone replacement therapy (HRT) was halted after an interim analysis found that the drugs — a combination of estrogen and progestin — increased the risk of breast cancer, stroke, and heart disease, and that those risks outweighed reduced risks of colorectal cancer and bone fractures (ScienceNOW, 9 July).

Women might still need to undergo chemotherapy or radiation therapy after their surgery — treatments that are known to reduce the risk of cancer recurring — which could delay their recovery further.

«Initial data from TAILORx breast cancer trial published: TAILORx trial finds 99 percent of women with low Oncotype DX ® Recurrence Score ® are free of breast cancer recurrence after 5 years of hormone therapy alone.»

This high mortality is primarily caused by resistance to therapy and the diagnosis of ovarian cancer after it has already metastasized, which occurs in approximately 80 percent of patients.

This is especially concerning because radiation therapy is increasingly being used after mastectomy as a way to further reduce the risk of the cancer returning in women with more aggressive or advanced disease.

Omission of radiotherapy is a reasonable option for women age 65 or older who receive hormone therapy after breast - conserving surgery for hormone receptor - positive, axillary node - negative breast cancer, according to results of the PRIME 2 trial presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10cancer, according to results of the PRIME 2 trial presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10Cancer Symposium, held Dec. 10 - 14.

«We found that CSM is statistically significantly lower for Asian Americans than for non-Hispanic whites overall, despite similarities in odds of receiving definitive therapy, and even after adjusting for socio - demographic factors, cancer stage and treatment,» said Trinh.

Reports of amazing recoveries abound, where patients remain cancer - free many years after receiving the therapy.

After excluding patients with liver cancer before the follow ‐ up index dates, 1,553 patients who had continuously received daily aspirin for at least 90 days were randomly matched 1:4 with 6,212 patients who had never received anti platelet therapy by means of propensity scores consisting of baseline characteristics, the index date and nucleos (t) ide analogue (NA) use during follow ‐ up.

In the first new study, Dr. Sharifi and colleagues from Memorial Sloan Kettering Cancer Center, Harvard / Dana - Farber Cancer Institute and University of Michigan Comprehensive Cancer Center analyzed 213 men whose prostate cancer recurred after radiation therapy and underwenCancer Center, Harvard / Dana - Farber Cancer Institute and University of Michigan Comprehensive Cancer Center analyzed 213 men whose prostate cancer recurred after radiation therapy and underwenCancer Institute and University of Michigan Comprehensive Cancer Center analyzed 213 men whose prostate cancer recurred after radiation therapy and underwenCancer Center analyzed 213 men whose prostate cancer recurred after radiation therapy and underwencancer recurred after radiation therapy and underwent ADT.

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

Additional cancer risk factors were older age, receipt of hormone replacement therapy and smoking, but after controlling for these risk factors, fat ratio remained an independent risk factor.

The study used surveys to explore the initiation and continuation of prescribed hormonal therapy, reaching 712 women 9 months after a breast cancer diagnosis and then again 4 years later (this maintenance therapy generally lasts 5 - 10 years).

Radiotherapy to the chest wall and regional lymph nodes (under the arm, above the collar bone and under the breast bone), known as regional nodal irradiation, is used after mastectomy in women with node - positive breast cancer who are treated with adjuvant systemic therapy.

Contrast - enhanced digital mammography is comparable to breast MRI in evaluating residual breast cancer after neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers today at the 2017 San Antonio Breast Cancer Sympcancer after neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers today at the 2017 San Antonio Breast Cancer SympCancer Symposium.

After adjusting for clinical factors in a multivariate model, a CNA in a CFS was determined to be a significant independent predictor of decreased response to radiation therapy and higher incidence of recurring cancer.

It is commonly thought that bladder cancers that develop after pelvic radiation tend to be aggressive, with high grades and stages, but this study found that the types, grades, and stages of bladder cancer that developed were similar in patients treated with and without radiation therapy.

A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.

This research could have important implications for cancer survivors, given that hypopituitarism is one of the main causes of poor quality of life after brain radiation therapy.

Clinicians should be aware of a small increased risk of second primary cancers after radiation therapy compared with men receiving surgery.

«Most renal cell carcinomas learn to escape therapy after a couple of years,» said Robert Weiss, professor of medicine at UC Davis, chief of nephrology at Sacramento VA Medical Center, and head of the kidney cancer working group at the UC Davis Comprehensive Cancer Ccancer working group at the UC Davis Comprehensive Cancer CCancer Center.

If it proves as effective in people as it is in mice, a vaccine could one day be given to cancer patients after surgery, radiation therapy, or chemotherapy to prevent tumors from regrowing.